Casswell Edward, Fernandez-Sanz Guillermo, Mitry Danny, Luk Sheila, Zakir Rahila
Department of Ophthalmology, Western Eye Hospital, London NW1 5QH, UK ; Moorfields Eye Hospital, London EC1V 2PD, UK.
Department of Ophthalmology, Western Eye Hospital, London NW1 5QH, UK.
Case Rep Ophthalmol Med. 2014;2014:403461. doi: 10.1155/2014/403461. Epub 2014 Dec 14.
Ocriplasmin is a protease which has been approved for the treatment of symptomatic vitreomacular adhesion (VMA). A 63-year-old presented with blurred vision in the left eye and a best corrected visual acuity of 6/18. Optical coherence tomography revealed VMA with an underlying macular hole and she subsequently underwent a left intravitreal ocriplasmin injection. One week after the injection, VMA had been released but with enlargement of the macular hole and a drop in her BCVA to 6/60. This persisted at 1 month after the injection. It is important to warn patients that ocriplasmin may lead to an enlargement of their macular hole with resultant loss in visual acuity.
奥克纤溶酶是一种已被批准用于治疗症状性玻璃体黄斑粘连（VMA）的蛋白酶。一名63岁患者左眼视力模糊，最佳矫正视力为6/18。光学相干断层扫描显示存在VMA并伴有黄斑裂孔，随后她接受了左眼玻璃体内注射奥克纤溶酶。注射后一周，VMA已松解，但黄斑裂孔扩大，其最佳矫正视力降至6/60。注射后1个月时仍维持这种情况。重要的是要告知患者，奥克纤溶酶可能导致黄斑裂孔扩大，从而导致视力下降。
